Small-molecule CFTR inhibitors slow cyst growth in polycystic kidney disease.
Cyst expansion in polycystic kidney disease (PKD) involves progressive fluid accumulation, which is believed to require chloride transport by the cystic fibrosis transmembrane conductance regulator (CFTR) protein. Herein is reported that small-molecule CFTR inhibitors of the thiazolidinone and glycine hydrazide classes slow cyst expansion in in vitro and in vivo models of PKD. More than 30 CFTR inhibitor analogs were screened in an MDCK cell model, and near-complete suppression of cyst growth was found by tetrazolo-CFTR(inh)-172, a tetrazolo-derived thiazolidinone, and Ph-GlyH-101, a phenyl-derived glycine hydrazide, without an effect on cell proliferation. These compounds also inhibited cyst number and growth by >80% in an embryonic kidney cyst model involving 4-d organ culture of embryonic day 13.5 mouse kidneys in 8-Br-cAMP-containing medium. Subcutaneous delivery of tetrazolo-CFTR(inh)-172 and Ph-GlyH-101 to neonatal, kidney-specific PKD1 knockout mice produced stable, therapeutic inhibitor concentrations of >3 microM in urine and kidney tissue. Treatment of mice for up to 7 d remarkably slowed kidney enlargement and cyst expansion and preserved renal function. These results implicate CFTR in renal cyst growth and suggest that CFTR inhibitors may hold therapeutic potential to reduce cyst growth in PKD.
Yang
Baoxue
B
Department of Medicine, University of California, San Francisco, San Francisco, CA, USA.
Sonawane
Nitin D
ND
Zhao
Dan
D
Somlo
Stefan
S
Verkman
A S
AS
D000818:Animals; D015820:Cadherins / Q000235:genetics; D002460:Cell Line; D019005:Cystic Fibrosis Transmembrane Conductance Regulator / Q000037:antagonists & inhibitors*; D004285:Dogs; D005998:Glycine / Q000031:analogs & derivatives* / Q000494:pharmacology / Q000627:therapeutic use; D019426:Integrases / Q000235:genetics / Q000378:metabolism; D007668:Kidney / Q000473:pathology; D051379:Mice; D008810:Mice, Inbred C57BL; D016891:Polycystic Kidney, Autosomal Dominant / Q000188:drug therapy* / Q000473:pathology; D050396:TRPP Cation Channels; D053778:Thiazolidines / Q000494:pharmacology / Q000627:therapeutic use*
D015820:Cadherins; D019005:Cystic Fibrosis Transmembrane Conductance Regulator; D005998:Glycine; D019426:Integrases; D050396:TRPP Cation Channels; D053778:Thiazolidines; C491946:Cdh16 protein, mouse; C051650:glycine hydrazide; C045073:Cre recombinase